中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
21期
88-89
,共2页
慢性乙型肝炎%拉米夫定%阿德福韦酯%HBeAg阳性
慢性乙型肝炎%拉米伕定%阿德福韋酯%HBeAg暘性
만성을형간염%랍미부정%아덕복위지%HBeAg양성
Chronic hepatitis B%Lamivudine%Adefovir dipivoxil%HBeAg positive
目的：探究拉米夫定与阿德福韦酯对治疗HBeAg阳性慢性乙型肝炎的效果差异。方法选取2011年6月~2013年6月期间于我院接受门诊治疗的HBeAg阳性慢性乙型肝炎患者72例进行回顾性分析，其中36例采用拉米夫定治疗，作为拉米夫定组，36例采用阿德福韦酯治疗，作为阿德福韦酯组，连续治疗与监测24个月。观察患者24个月后血清ALT的复常率、血清HBV DNA转阴率、HBeAg 消失率、HBeAg转阴率等。结果拉米夫定组患者的ALT复常率、HBV DNA转阴率、HBeAg消失率、HBeAg血清转换率均随着治疗时间的加长而逐渐降低，阿德福韦酯组患者则相反，两组相比较，差异有统计学意义（P＜0.05）。结论拉米夫定起效快，但耐药率高，适合重症患者；阿德福韦酯虽起效慢，但2年耐药率低，对非重症患者作为首选药物。
目的：探究拉米伕定與阿德福韋酯對治療HBeAg暘性慢性乙型肝炎的效果差異。方法選取2011年6月~2013年6月期間于我院接受門診治療的HBeAg暘性慢性乙型肝炎患者72例進行迴顧性分析，其中36例採用拉米伕定治療，作為拉米伕定組，36例採用阿德福韋酯治療，作為阿德福韋酯組，連續治療與鑑測24箇月。觀察患者24箇月後血清ALT的複常率、血清HBV DNA轉陰率、HBeAg 消失率、HBeAg轉陰率等。結果拉米伕定組患者的ALT複常率、HBV DNA轉陰率、HBeAg消失率、HBeAg血清轉換率均隨著治療時間的加長而逐漸降低，阿德福韋酯組患者則相反，兩組相比較，差異有統計學意義（P＜0.05）。結論拉米伕定起效快，但耐藥率高，適閤重癥患者；阿德福韋酯雖起效慢，但2年耐藥率低，對非重癥患者作為首選藥物。
목적：탐구랍미부정여아덕복위지대치료HBeAg양성만성을형간염적효과차이。방법선취2011년6월~2013년6월기간우아원접수문진치료적HBeAg양성만성을형간염환자72례진행회고성분석，기중36례채용랍미부정치료，작위랍미부정조，36례채용아덕복위지치료，작위아덕복위지조，련속치료여감측24개월。관찰환자24개월후혈청ALT적복상솔、혈청HBV DNA전음솔、HBeAg 소실솔、HBeAg전음솔등。결과랍미부정조환자적ALT복상솔、HBV DNA전음솔、HBeAg소실솔、HBeAg혈청전환솔균수착치료시간적가장이축점강저，아덕복위지조환자칙상반，량조상비교，차이유통계학의의（P＜0.05）。결론랍미부정기효쾌，단내약솔고，괄합중증환자；아덕복위지수기효만，단2년내약솔저，대비중증환자작위수선약물。
Objective To explore the result differences between the treatment of HBeAg positive chronic hepatitis B by using lamivudine and adefovir dipivoxil. Methods 72 HBeAg positive chronic hepatitis B patients who took the ambulatory treatment at our hospital during June 2011 to June 2013 had been selected to make the retrospective analysis, among it, 36 patients were taken the treatment by using lamivudine as the lamivudine group, and 36 patients were taken the treatment by using adefovir dipivoxil as the adefovir dipivoxil group. The continuous treatment and monitoring had been taken for them for 24 months, and after 24 months, the recovery rate of the blood serum ALT, the negative conversion ratio of the blood serum HBV DNA, the fade rate of HBeAg and the negative conversion ratio of HBeAg and etc of them were observed. Results The ALT recovery rate, the HBV DNA negative conversion ratio, the HBeAg fade rate, the HBeAg seroconversion rate of the patients in the lamivudine group were gradually reduced with the increase of time of therapy, while the patients in adefovir dipivoxil group were contrary. Compared the two groups, through the statistical analysis, the differences were significant (P < 0.05). Conclusion The effect of lamivudine is rapid but the drug resistance rate is high, which is suitable for the critical patients. And, although the effect of the adefovir dipivoxil is slow, but the drug resistance rate in 2 years is low, which is the priority drug for the non-critical patients.
